LONDON, Feb 28 (Reuters) - The top management of Antisoma stepped down on Monday as the Briti
sh cancer specialist cut its operations following the failure of its two leading drug candidates.
The company's leukaemia drug candidate AS1413 failed in a final-stage trial in January, delivering a second blow after the failure of a lung cancer drug, its biggest hope, in March 2010. [ID:nLDE70U090}
Chief Executive Glyn Edwards and finance director Eric Dodd had both resigned, the company said, although Dodd will continue to advises the firm on strategic options, which includes a sale of the company.
Shares in Antisoma, once one of Britain's brightest biotech hopes, were valued at more than 200 pence in March 2000 when the sector was riding high.
COPYRIGHT Copyright Thomson Reuters 2011. All rights reserved. The copying, republication or redistribution of Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
Datafeed and UK data supplied by NETbuilder and Interactive Data.
While London South East do their best to maintain the high quality of the information displayed on this site,
we cannot be held responsible for any loss due to incorrect information found here. All information is provided free of charge, 'as-is', and you use it at your own risk!
The contents of all 'Chat' messages should not be construed as advice and represent the opinions of the authors, not those of London South East Limited, or its affiliates.
London South East does not authorise or approve this content, and reserves the right to remove items at its discretion.